Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502446 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
A Phase 1 study, sponsored by CRISPR Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT04502446 is a Phase 1 study that was terminated before completion, run by CRISPR Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT04502446, a Phase 1 study, was terminated before completion, sponsored by CRISPR Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
Interventions
- BIOLOGICAL CTX130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-07-31 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502446
The ClinicalTrials.gov registry entry for NCT04502446 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTX130 is the first listed.
NCT04502446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502446 about?
NCT04502446 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)". This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
What is the current status of trial NCT04502446?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2020-07-31. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04502446?
The interventions under investigation include: CTX130 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04502446?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.